Review Article

Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2 Lymphadenectomy

Qiong Yang,1 Ying Wei,1 Yan-Xian Chen,1 Si-Wei Zhou,2 Zhi-Min Jiang,1 and De-Rong Xie1

1 Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
2 Department of Oncology, Huizhou Center Hospital, Huizhou 516001, China

Correspondence should be addressed to De-Rong Xie; xiederong@126.com

Received 2 August 2013; Accepted 29 August 2013

Academic Editor: Qiang Xia

Copyright © 2013 Qiong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Little data on directly comparing chemoradiotherapy with observation has yet been published in the setting of adjuvant therapy for resected gastric cancer who underwent D2 lymphadenectomy. The present indirect comparison aims to provide more evidence on comparing the two approaches.

Methods. We conducted a systematic review of randomized controlled trials, extracted time-to-event data using Tierney methods (when not reported), and performed indirect comparison to obtain the relative hazards of adjuvant chemoradiotherapy to observation on overall and disease-free survival.

Results. Seven randomized controlled trials were identified. Three trials compared adjuvant chemoradiotherapy with adjuvant chemotherapy, and 4 trials compared adjuvant chemotherapy with observation. Using indirect comparison, the relative hazards of adjuvant chemoradiotherapy to observation were 0.43 (95% CI: 0.33–0.55) in disease-free survival and 0.52 (95% CI: 0.38–0.71) in overall survival for completely resected gastric cancer with D2 lymphadenectomy.

Conclusions. Postoperative chemoradiotherapy can prolong survival and decrease recurrence in patients with resected gastric cancer who underwent D2 gastrectomy. Molecular biomarker might be a promising direction in the prediction of clinical outcome to postoperative chemoradiotherapy, which warranted further study.

1. Introduction

Gastric cancer is the third leading cause of cancer-related death among men and the fifth among women in the worldwide [1]. The primary curative treatment of gastric carcinoma is surgical resection [2]. Complete resection with adequate margins is widely considered as a standard goal, whereas the extent of lymph node dissection remains controversial. Irrespective of the surgical procedure used for the treatment of gastric cancer, the effectiveness of surgical resection is poor; about 60% eventually have local relapse or distant metastases after curative resection [3]. The high rate of relapse or distant metastases after resection make it important to consider adjuvant treatment for patients with resected gastric cancer.

The INT-0116 trial [4, 5], the largest phase III trial comparing chemoradiotherapy versus observation, shows that adjuvant chemoradiotherapy prolonged overall survival (OS) and relapse-free survival (RFS). In this trial, 10% of the patients underwent D2 dissection, suggesting that chemoradiotherapy might be only compensating for inadequate surgery. Therefore, the role of chemoradiation therapy after D2 dissection has been questioned. Two retrospective studies demonstrated that adjuvant chemoradiotherapy was well tolerated with acceptable toxicities and reasonable tumor control for patients with D2 gastrectomy [6, 7]. Another retrospective study does not demonstrate that adjuvant chemoradiotherapy reduce relapse and impact on survival [8]. There is no RCT comparing adjuvant chemoradiotherapy with observation D2-dissected gastric cancer. In view of the paucity of data, we attempted to answer this question using the method of adjusted indirect comparison.

2. Methods

2.1. Literature Search. A systematic review of eligible RCTs was performed by searching the electronic databases, which
consist of Cochrane Central Register of Controlled Trials, Medline, EMBASE, ISI Web of Knowledge, ASCO abstracts, and ESMO abstracts. The deadline of this search was June 30, 2013. The keywords were used for search in electronic databases as follows: “gastric cancer,” “Stomach Neoplasms,” “chemoradiotherapy,” “chemoradiation,” “Chemotherapy,” “D2”, and “Combined Modality Therapy.” The search was limited to RCTs in English language. The reference lists of articles were identified, and relevant meta-analysis were analyzed manually to find other relevant articles.

2.2. Trial Selection and Quality Assessment. All RCTs that compared chemotherapy with observation or compared chemoradiotherapy with chemotherapy in adjuvant therapy for resected gastric cancer were included in the present study. If the same population appeared in other publications, the article that provided the most complete follow-up data on survival was selected. Methodological quality of the trials was assessed using a validated scale (range, 0 to 5) applied to items that influence intervention efficacy. The scale consists of items pertaining to randomization, masking, dropouts, and withdrawals, which is reported by Jadad et al. [9]. Trial was regarded as high quality trial and had high external and internal validities if it was scored by more than 3 points.

2.3. Data Extraction. Two primary reviewers assessed all abstracts that were identified from the above-mentioned sources. Both reviewers independently selected potentially eligible abstracts according to inclusion criteria. If one of the reviewers concluded an abstract that might be eligible, the complete article was retrieved and reviewed in detail by both reviewers. Disagreements were resolved by consensus or by the third reviewer. Hazard ratio (HR) and 95% confidence interval (95% CI) for OS and DFS were requested. Where published, HR and 95% CI were extracted directly from the original article. Where HR and 95% CI were not reported, they were calculated from published summary statistics or survival curve using Tierney et al. method [10]. The following variables were extracted from each trial if available: first author’s name, publication year, country of origin, treatment regimen, total numbers of patients, percentage of different stages, percentage of T3 and T4 stage, percentage of lymph node positive, HR and 95% CI for OS and DFS, and median follow-up time.

2.4. Brief Introduction of Adjusted Indirect Comparison. Suppose that interventions A and C were directly compared in a RCT, and another trial compared intervention B with intervention C. To compare intervention A with intervention B, a method of adjusted indirect comparison can be used to realize it [11]. Briefly, the log hazard ratio (log HR) of the adjusted indirect comparison for intervention A versus B was estimated by \( \log HR_{AB} = \log HR_{AC} - \log HR_{BC} \) and its standard error for the log HR was \( SE(\log HR_{AC}) = \sqrt{SE(\log HR_{AC})^2 + SE(\log HR_{BC})^2} \).

Where \( \log HR_{AC} \) was the log HR for the direct comparison of intervention A versus C and \( \log HR_{BC} \) were the log HR for the direct comparison of intervention B versus C. \( SE(\log HR_{AC}) \) was the standard error of the log HR for the direct comparison of intervention A versus C and \( SE(\log HR_{AC}) \) was the standard error of the log HR for the direct comparison of intervention B versus C. The strong underlying assumption in this adjusted indirect comparison method is that the relative efficacy of an intervention is consistent in patients included in different trials. That is, log \( HR_{AC} \) observed in trials comparing A versus C is assumed to be log \( HR_{BC} \) that would have been observed in those trials comparing B versus C and vice versa.

2.5. Statistical Analysis. To combine the results of individual trial’s HR for comparing chemoradiotherapy with chemotherapy or comparing observation with chemotherapy, direct meta-analysis was used. Heterogeneity assumption was checked by a chi-square-based Q-test and also expressed as \( I^2 \). A \( P \) value of more than 0.10 for the Q-test and \( I^2 \) of less than 50% indicated a lack of heterogeneity across the trials. If \( P \)-value of heterogeneity test was more than 0.1 and \( I^2 \) was less than 50%, fixed effects model was performed and random effects model was used vice versa.

Adjusted indirect comparison was used to evaluate the relative efficacy of chemoradiotherapy to observation. The primary endpoint was OS, and the secondary endpoint was DFS. Treatment effect size was calculated by HR and 95% CI. Due to the adjusted indirect comparison using the fixed effect model which tended to underestimate standard errors of pooled estimates, random effect model was used for the quantitative pooling in the adjusted indirect comparison. A HR value of less than 1 stands for favoring chemoradiotherapy arm and a HR value of more than 1 stands for favoring chemotherapy arm. All CIs had a two-sided probability coverage of 95%. A statistical test with a \( P \) value less than 0.05 was considered significant, and all \( P \) values were two-sided.

All analyses were performed strictly with RevMan software (version 5.2, Cochrane).

3. Results

3.1. Trial Flow, Characteristics, and Quality Appraisal. Figure 1 was the flow chart of RCTs selection for this study. Seven trials were identified at last [12–18]. Three trials compared chemoradiotherapy with chemotherapy. Four trials directly compared observation with chemotherapy. Six out of 7 trials were conducted in Asian countries, but only one trial was from European country. Almost all patients (>95%) underwent curative gastrectomy with D2 lymphadenectomy. Table 1 showed important baseline characteristics and Jadad scores of selected trials.

3.2. Adjusted Indirect Comparison. First, we use a method of meta-analysis to combine the pooled result for chemoradiotherapy versus chemotherapy and observation versus
2100 of the records were identified through electronic databases searching (Cochrane Central Register of Controlled Trials, Medline, EMBASE, ISI Web of Knowledge, and ASCO and ESMO abstracts)

1669 of the records after duplicates were removed

1538 of the records were excluded after abstract review
17 methodologies or pharmacologic studies
48 meta-analysis or retrospective studies
306 case-control studies or cohort studies
301 reviews, editorials, or guidelines
231 investigated immunotherapy, radiotherapy, or perioperative or intraperitoneal chemotherapy
635 other topics

131 of full-text articles were assessed for eligibility

113 excluded
46 did not use surgery alone as comparator
21 were not randomized
18 review articles
10 full-text not available
9 updated previously published data
6 investigated radiotherapy, perioperative chemotherapy
2 did not conduct curative resection
1 type of lymphadenectomy not clear

18 of the studies were included in qualitative synthesis

11 excluded
1 data not available
10 D0/D1 lymphadenectomy was used

7 of the studies were included in qualitative synthesis

Figure 1: Flow chart of randomized controlled trials selection.

Chemotherapy. The pooled HR and 95% CI were 0.72 (0.59–0.89) in DFS and 0.79 (0.61–1.03) in OS for chemoradiotherapy versus chemotherapy. The pooled HR and 95% CI were 1.68 (1.46–1.93) in DFS and 1.52 (1.30–1.79) in OS for observation versus chemotherapy.

Second, adjusted indirect comparison was computed for estimating the relative efficacy of adjuvant chemoradiotherapy to observation. Compared with observation, chemoradiotherapy significantly improved DFS and OS for patients with D2-resected gastric cancer. The pooled HR and 95%
| References | Countries | Regimens | N  | I/II/III/IV (%) | T3/4 (%) | N+ (%) | DFS HR (95% CI) | OS HR (95% CI) | Median (range) Follow-up (month) | Jadad score |
|------------|-----------|----------|----|----------------|----------|--------|-----------------|----------------|-------------------------------|-------------|
| Chemoradiotherapy versus chemotherapy | | | | | | | | | | |
| Lee et al. 2012 [12] | Korea | XP/XRT/XP | 230 | 21.3/36.5/30.8/11.3 | NR | 88.3 | 0.73 (0.52–1.04) | — | 53.2 (36.9–77.3) | 3 |
| | | XP | 228 | 21.9/37.7/28.6/11.8 | NR | 84.6 | — | — | — | — |
| Zhu et al. 2012 [13] | China | RT/FL | 168 | 10.8/19.4/55.4/14.5 | 100 | 84.9 | 0.74 (0.56–0.97) | 0.80 (0.6–1.06) | 42.5 | 3 |
| | | FL | 165 | 9.1/18.2/58.2/14.5 | 100 | 86.7 | — | — | — | — |
| Kim et al. 2012 [14] | Korea | RT/FL | 46 | 0/0/73.9/26.1 | 69.5 | 100 | 0.62 (0.33–1.14) | 0.76 (0.39–1.48) | 86.7 (60.3–116.5) | 3 |
| | | FL | 44 | 0/0/75/25 | 56.8 | 95.4 | — | — | — | — |
| Observation versus chemotherapy | | | | | | | | | | |
| Cirera et al. 1999 [15] | Spain | MMC/tegafur | 76 | 0/0/100/0 | 92 | 80 | 1.82 (1.18, 2.79) | 1.67 (1.08, 2.57) | 37 (3–122) | 4 |
| | | Observation | 72 | 0/0/100/0 | 89 | 97 | — | — | — | — |
| Nakajima et al. 2007 [16] | Japan | Uracil-tegafur | 93 | 0/100/0/0 | 0 | 100 | 2.27 (1.28, 1.04) | 2.08 (1.13, 3.85) | 74.4 | 5 |
| | | Observation | 95 | 0/100/0/0 | 0 | 100 | — | — | — | — |
| Sasako et al. 2011 [17] | Japan | S-1 | 529 | 0.2/49.9/42.3/7.6 | 45.1 | 90.4 | 1.54 (1.27, 1.86) | 1.49 (1.20, 1.85) | 60 | 3 |
| | | Observation | 530 | 0/53.2/40.2/6.6 | 46.1 | 879 | — | — | — | — |
| Bang et al. 2012 [18] | Korea | XELOX | 520 | 1/49.5/0 | 45 | 91 | 1.79 (1.40, 2.28) | 1.39 (1.00, 1.93) | 34.2 (25.4–41.7) | 3 |
| | | Observation | 515 | 0/51/49/0 | 45 | 89 | — | — | — | — |

RCTs: randomized controlled trials; N: number of patients; I/II/III/IV: cancer stage; IV refers to T4N1-3M0 and T1-3N3M0; T3/4: percentage of T3 and T4 stage; N+: percentage of node positive; DFS: disease-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval.
NR: not report.
XP: capecitabine + cisplatin; XRT: radiotherapy with capecitabine; RT: radiotherapy; FL: fluorouracil plus leucovorin; MMC: mitomycin; XELOX: oxaliplatin + capecitabine.
Several trials have shown strong benefit from adjuvant chemoradiotherapy in patients with D2-resected gastric cancer. Overall, our data demonstrated the reasonable tumor control benefit from adjuvant chemoradiotherapy to observation in completely adjusted indirect comparison method to estimate the efficacy of adjuvant chemoradiotherapy to observation (Table 2).

To explore the potential influence on survival benefit by geographic difference, we reevaluated the pooled HR for observation to chemotherapy by omitting the trial from Spain. The pooled HR for observation to chemotherapy was 1.66 (1.44–1.92) in DFS and 1.50 (1.26–1.78) in OS, respectively. Accordingly, the pooled HR for indirect comparison of chemoradiotherapy to observation was 0.43 (0.34–0.56) in DFS and 0.53 (0.38–0.72) in OS, respectively (Table 2).

### Table 2: Indirect comparison on the efficacy of chemoradiotherapy versus observation for resected gastric cancer after D2 lymphadenectomy.

| CRT versus Obs in comparison | Number of trials | Hazard ratio (95% CI) | P value |
|------------------------------|------------------|-----------------------|---------|
| DFS                          | 7                | 0.43 (0.33, 0.55)     | 0.00    |
|                              | 6*               | 0.43 (0.34, 0.56)     | 0.00    |
| OS                           | 6                | 0.52 (0.38, 0.71)     | 0.00    |
|                              | 5*               | 0.53 (0.38, 0.72)     | 0.00    |

CRT: chemoradiotherapy, Obs: observation, 95% CI: 95% confidence interval, DFS: disease-free survival, and OS: overall survival. * Subgroup analysis after omitting the trial from Spain.

CI were 0.43 (0.33–0.55) in DFS and 0.52 (0.38–0.71) in OS, respectively. Table 2 summarized those estimates of indirect comparison for D2-resected gastric cancer.

#### 3.3. Subgroup Analyses.

To explore the potential influence on survival benefit by geographic difference, we reevaluated the pooled HR for observation to chemotherapy by omitting the trial from Spain and did further indirect comparison of chemoradiotherapy to observation. The pooled HR for observation to chemotherapy was 1.66 (1.44–1.92) in DFS and 1.50 (1.26–1.78) in OS, respectively. Accordingly, the pooled HR for indirect comparison of chemoradiotherapy to observation was 0.43 (0.34–0.56) in DFS and 0.53 (0.38–0.72) in OS, respectively (Table 2).

### 4. Discussion

In the last decade, postoperative chemoradiotherapy has become the preferred strategy for resected gastric cancer in the United States because the INT-0116 trial suggested that postoperative chemoradiotherapy had a survival advantage over observation. However, adoption of this regimen has been somewhat tempered in Asian countries. The main reason was the inadequate node dissection (only 10% had a D2 dissection) in INT-0116. Recently, gastrectomy with D2 lymphadenectomy becomes the standard treatment for curable gastric cancer in Eastern Asia. Thus, the efficacy of adjuvant chemoradiotherapy should be established in patients with D2-resected gastric cancer.

To evaluate the relative efficacy of treatment approaches, the most reliable evidence comes from head-to-head RCTs. However, there is usually no direct randomized evidence or no sufficient direct randomized evidence. In this situation, adjusted indirect comparison of different interventions can be used to give an alternative estimation. It is reported that results of adjusted indirect comparison usually, but not always, agree with those of head to head randomized trials [19]. Due to insufficient direct evidence, we used an adjusted indirect comparison method to estimate the efficacy of adjuvant chemoradiotherapy to observation in completely resected gastric cancer. Overall, our data demonstrated strong benefit from adjuvant chemoradiotherapy in patients with D2-resected gastric cancer.

A Singapore retrospective study reports the clinical outcomes of 67 patients who were mostly treated with D2 node dissection and received adjuvant chemoradiotherapy as per INT-0116. The 3-year overall survival, disease-free survival, and local control are 60.6%, 54.1%, and 84.3%, respectively. Of the 30 patients who relapsed, 5 (17%) have isolated locoregional recurrences only. This retrospective study shows reasonable tumor control benefit from adjuvant chemoradiotherapy [6]. Comparable results were also showed in a Korean retrospective observational study with over 500 cases after D2 gastrectomy [7]. On the other hand, 3-year overall survival, disease-free survival, and local control in chemotherapy arm are 80.1%, 72.2%, and 75% in ACTS-GC trial, respectively [17]. Similarly, 3-year disease-free survival and local control in chemotherapy arm are 74% and 82% in CLASSIC trial, respectively [18]. Although simple horizontal comparison is unscientific, it seemed that chemoradiotherapy arm of two retrospective studies did not show an advantage over chemotherapy arm of ACTS-GC and CLASSIC trials. To date, 3 head-to-head trials compare chemoradiotherapy versus chemotherapy for those patients without positive results reported [12–14]. Furthermore, pooled analysis of these 3 trials also does not demonstrate that chemoradiotherapy has any survival advantage over chemotherapy [20].

The reason that chemoradiotherapy did not have any survival advantage over chemotherapy in D2-resected gastric cancer was not well understood. It has been reported that the sites of treatment failure after surgical treatment were mainly locoregional in the tumor bed in Western countries [21]. In contrast, in Asian countries, the sites of treatment failure were mainly distant metastasis [20]. The discrepancy is mainly due to a high percentage of diffuse-type histology gastric cancer in Asian population, which accounted for 50% at least [22]. Diffuse gastric cancer is characterized by decreased intracellular adhesion as a result of E-cadherin mutation and/or hypermethylation and is prone to early metastasis. Therefore, chemoradiotherapy does not appear to confer a benefit to diffuse gastric cancer [23].

There are studies to explore the role of molecular biomarkers in predicting clinical outcome to chemoradiotherapy. A study evaluates the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemoradiotherapy in 44 patients with resected gastric cancer. It indicates that 75% of relapse patients show Lys/Lys genotype more frequently (P = 0.042). The Lys polymorphism is an independent predictor of high-risk relapse-free survival from statistical analysis (HR: 3.07, 95% CI: 1.07–8.78, P = 0.036) [24]. Recently, INT-0116 group reports result of a retrospective analysis on the prognostic value of HER2 in adjuvant therapy choice for gastric cancer. Patients are from INT-0116 phase III gastric cancer clinical trial. Among patients with HER2-nonamplified cancers, treated patients have a median OS of 44 months compared with 24 months in the surgery-only arm (P = 0.003). Among patients with HER2-amplified cancers, there is no significant difference in survival based on treatment arm. HER2 status is not a prognostic marker among patients who received no postoperative chemoradiotherapy [25]. In short, molecular biomarkers might be a promising direction to screen the
patients who benefit from postoperative chemoradiotherapy, which warranted further study.

There were several important limitations to our study. First, patient characteristics might be different among selected trials. Cancer stage in the majority of trials was at more advanced stage, including stage II/III, T3/4, and N+ patients, in contrast to the greater proportion of stage I and less proportion of T3/4 patients included in the Nashimoto et al. trial. However, the result of adjusted indirect comparison was not materially altered after omitting this trial (data not shown). Second, because only the published literature and English literature were reviewed for the study, there is the potential for results to be influenced by publication bias and selection bias. Third, the treatment protocols among included RCTs were different with each other. However, due to limited number of the final included RCTs, we did not perform subgroup analysis based on treatment protocols. That is, head to head comparison is needed urgently in future. At last, 6 out of 7 eligible trials were from Asia, making the result less generalized to other region.

5. Conclusions

Based on indirect comparison, chemoradiotherapy demonstrated strong survival advantage over observation in patients with D2-resected gastric cancer. We confirmed the role of adjuvant chemoradiotherapy in D2-resected gastric cancer patients from a different perspective. At present, there are studies which reported that molecular biomarkers might predict clinical outcome to chemoradiotherapy, which was helpful to develop individualized therapy and warranted further study.

Conflict of Interests

There are no financial or nonfinancial competing interests to declare in relation to this paper by any of the authors.

Authors’ Contribution

Qiong Yang and Ying Wei contribute equally.

References

[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[2] J. S. Macdonald, “Role of post-operative chemoradiation in resected gastric cancer,” Journal of Surgical Oncology, vol. 90, no. 3, pp. 166–170, 2005.
[3] O. Bouché, M. Ychou, P. Burtin et al., “Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801),” Annals of Oncology, vol. 16, no. 9, pp. 1488–1497, 2005.
[4] J. S. Macdonald, S. R. Smalley, J. Benedetti et al., “Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction,” The New England Journal of Medicine, vol. 345, no. 10, pp. 725–730, 2001.
[5] S. R. Smalley, J. K. Benedetti, D. G. Haller et al., “Updated analysis of SOWG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection,” Journal of Clinical Oncology, vol. 30, no. 19, pp. 2327–2333, 2012.
[6] C. N. Leong, H. T. Chung, K. M. Lee et al., “Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma,” Cancer Journal, vol. 14, no. 4, pp. 269–275, 2008.
[7] S. Kim, D. H. Lim, J. Lee et al., “An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 5, pp. 1279–1285, 2005.
[8] S. H. Park, D. Y. Kim, J. S. Heo et al., “Postoperative chemoradiotherapy for gastric cancer,” Annals of Oncology, vol. 14, no. 9, pp. 1373–1377, 2003.
[9] A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996.
[10] J. F. Tierney, L. A. Stewart, D. Gherzi, S. Burdett, and M. R. Sydes, “Practical methods for incorporating summary time-to-event data into meta-analysis,” Trials, vol. 7, no. 8, 2007.
[11] H. C. Bucher, G. H. Guyatt, L. E. Griffith, and S. D. Walter, “The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials,” Journal of Clinical Epidemiology, vol. 50, no. 6, pp. 683–691, 1997.
[12] J. Lee, D. H. Lim, S. Kim et al., “Phase III trial comparing capcitabine plus cisplatin versus capcitabine plus cisplatin with concurrent capcitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 268–273, 2012.
[13] W. G. Zhu, D. F. Xua, J. Pu et al., “A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection,” Radiotherapy and Oncology, vol. 104, no. 3, pp. 361–366, 2012.
[14] T. H. Kim, S. R. Park, K. W. Byu et al., “Phase 3 trial of postoperative chemoradiation alone versus chemoradiation therapy in stage III-IV gastric cancer treated with Ro gastrectomy and D2 lymph node dissection,” International Journal of Radiation Oncology, vol. 84, no. 5, pp. e585–e592, 2012.
[15] L. Cirera, A. Balil, E. Batiste-Alentorn et al., “Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer,” Journal of Clinical Oncology, vol. 17, no. 12, pp. 3810–3815, 1999.
[16] T. Nakajima, T. Kinoshita, A. Nashimoto et al., “Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer,” British Journal of Surgery, vol. 94, no. 12, pp. 1468–1476, 2007.
[17] M. Sasaki, S. Sakuramoto, H. Katai et al., “Five-year outcomes of a randomized phase III trial comparing adjuvant chemotheraphy with S-1 versus surgery alone in stage I or III gastric cancer,” Journal of Clinical Oncology, vol. 29, no. 33, pp. 4387–4393, 2011.
[18] Y. J. Bang, Y. W. Kim, H. K. Yang et al., “Adjuvant capcitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASICC): a phase 3 open-label, randomised controlled trial,” The Lancet, vol. 379, no. 9813, pp. 315–321, 2012.
[19] F. Song, D. G. Altman, A. M. Glenny, and J. J. Deeks, “Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses,” *British Medical Journal*, vol. 326, no. 7387, pp. 472–475, 2003.

[20] Y. Y. Huang, Q. Yang, S. W. Zhou et al., “Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis,” *PLoS ONE*, vol. 8, no. 7, Article ID e68939, 2013.

[21] J. Landry, J. E. Tepper, W. C. Wood, E. O. Moulton, F. Koerner, and J. Sullinger, “Patterns of failure following curative resection of gastric carcinoma,” *International Journal of Radiation Oncology Biology Physics*, vol. 19, no. 6, pp. 1357–1362, 1990.

[22] C. Hsu, Y. C. Shen, C. C. Cheng, A. L. Cheng, F. C. Hu, and K. H. Yeh, “Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression,” *Gastric Cancer*, pp. 1–16, 2012.

[23] G. A. Brooks, P. C. Enzinger, and C. S. Fuchs, “Adjuvant therapy for gastric cancer: revisiting the past to clarify the future,” *Journal of Clinical Oncology*, vol. 30, no. 19, pp. 2297–2299, 2012.

[24] R. N. R. Zárate, F. Arias, E. Bandres, E. Cubedo, R. Malumbres, and J. García-Foncillas, “Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy,” *World Journal of Gastroenterology*, vol. 12, no. 37, pp. 6032–6036, 2006.

[25] M. A. Gordon, H. M. Gundacker, J. Benedetti et al., “Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial,” *Annals of Oncology*, vol. 24, no. 7, pp. 1754–1761, 2013.